Trial Profile
A Multicenter, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 May 2020
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Coronary artery disease; Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Amgen
- 30 Mar 2020 Results presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology
- 20 Mar 2018 Status changed from active, no longer recruiting to completed.
- 20 Mar 2018 This trial has been Discontinued in Spain (on 2018-02-28).